Company: DAWN
Filing Date: 2025-03-06
Form Type: 10-K/A
Source: 0000950170-25-034878
Chunk: 55

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K/A
Chunk 55
---
 its specialty pharmacy and specialty distributor customers. All the Company’s assets are located in the United States.

In addition to the significant expense categories included within net loss presented on the Company's Statements of Operations, see below for disaggregated amounts that comprise research and development expenses:

|                                                                     |     | Year Ended    
 December 31,  |    2024 |     |   |    2023 |     |   |   2022 |
|:--------------------------------------------------------------------|:----|:--------------|--------:|:----|:--|--------:|:----|:--|-------:|
|                                                                     |     | -in thousands |         |     |   |         |     |   |        |
| External costs:                                                     |     |               |         |     |   |         |     |   |        |
| Third-party CRO, CMO and other third-party clinical trial costs (1) |     | $             |  89,400 |     | $ |  71,294 |     | $ | 50,175 |
| License upfront payments and milestones                             |     |               |  80,000 |     |   |   8,000 |     |   |  2,500 |
| Other research and development costs                                |     |               |   8,949 |     |   |   8,465 |     |   |  3,598 |
| Internal costs:                                                     |     |               |         |     |   |         |     |   |        |
| Employee related expenses                                           |     |               |  49,353 |     |   |  42,762 |     |   | 29,345 |
| Total research and development expenses                             |     | $             | 227,702 |     | $ | 130,521 |     | $ | 85,618 |

(1)

<div align='center'>F-35</div>